Merck Animal Health Completes Acquisition of Elanco’s Aqua Business

Acquisition provides industry-leading portfolio, science and research capabilities that will translate into greater value for customers

RAHWAY, NJ, July 9, 2024–(BUSINESS WIRE)–Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the completion of its acquisition of the aquaculture business of Elanco Animal Health Incorporated (NYSE: ELAN). The completion of this acquisition strengthens Merck Animal Health’s position in the aquaculture industry with a comprehensive approach to promoting fish health, welfare and sustainability in aquaculture, conservation and fisheries.

“With the completion of this acquisition, we are well positioned in the aquaculture industry with a strong and comprehensive portfolio spanning warm water, cold water, vaccines, parasiticides, water supplements and nutrition,” said Rick DeLuca, president of Merck Animal Health. “We are excited to welcome our new colleagues to Merck Animal Health and look forward to working together with a shared goal of healthier animal science.”^®.”

The acquisition brings innovative products to Merck Animal Health, including CLYNAV®, a next-generation DNA-based vaccine that protects Atlantic salmon against pancreatic disease, and IMVIXA®, an antiparasitic agent for the treatment of sea lice and water treatment for warm-water production, complementing Merck Animal Health’s vaccine portfolio.

The increasing use of drugs and vaccines, nutrients and supplements for aquatic species is driven by the increasing demand for protein and food safety, which ensures the supply of high-quality food and protects public health.

About Merck Animal Health

At Merck, known as MSD outside the United States and Canada, we are united around our purpose: harnessing the power of cutting-edge science to save and improve lives around the world. For more than a century, we have been at the forefront of research, introducing medicines, vaccines and innovative healthcare solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, NJ, USA, is the global animal health business of Merck. Through our commitment to the science of healthier animals,^®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the broadest ranges of pharmaceutical products, vaccines and health management solutions and services, as well as a broad set of connected technologies that includes products for identification, tracking and monitoring. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive research and development resources and a modern, global supply chain. Merck Animal Health has a presence in more than 50 countries, with products available in approximately 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and on Instagram.

The story continues

Prognostic Statement by Merck & Co., Inc., Rahway, NJ, USA

This press release from Merck & Co., Inc., Rahway, NJ, USA (the “company”) contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If the underlying assumptions prove inaccurate or if risks or uncertainties materialize, actual results could differ materially from those discussed in the forward-looking statements.

Risks and uncertainties include, among others, general industry conditions and competition; general economic factors, including fluctuations in interest rates and currency exchange rates; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward reducing healthcare costs; technological advances, new products and patents obtained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; difficulties or delays in manufacturing; financial instability in international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and exposure to litigation, including patent litigation and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available on the SEC’s website (www.sec.gov).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240702965019/en/

Communication

Media:
Who Gorode
(973) 255-8904
[email protected]

Michael Close
(310) 617-1067
[email protected]

Investors:
Peter Dannenbaum
(732) 594-1579
[email protected]